Globus Medical (GMED) has fallen about 17% over the past week, even as its recent quarterly report showed higher sales and earnings and reaffirmed full year revenue guidance, putting the stock under closer investor scrutiny.

The recent 30 day share price return is down 18.94%, adding to a weaker 90 day share price return of 13% and pointing to fading short term momentum, even as the 1 year total shareholder return is 25.13%.

If this kind of volatility has you looking beyond a single stock, it could be a good moment to scan the market for other healthcare companies using AI in meaningful ways through the 32 healthcare AI stocks

So with the stock down sharply even as earnings, guidance and value metrics look supportive, are you seeing a temporary reset in sentiment, or is the current US$76.64 price already factoring in the company’s future growth?

Most Popular Narrative: 31.3% Undervalued

At a last close of $76.64 versus a narrative fair value of $111.50, the current price sits well below what this widely followed framework implies.

Globus Medical is poised to benefit from growing global demand for spine and orthopedic solutions as the population ages and musculoskeletal disorders become more prevalent. This supports a long runway for expanding the addressable market and sustained top-line revenue growth.

Curious what has to happen for that higher value to make sense? The narrative leans on steady revenue gains, resilient margins, and a richer earnings multiple. The exact mix of those assumptions is where the story gets interesting.

Result: Fair Value of $111.50 (UNDERVALUED)

However, this narrative can break if prolonged sales cycles for robotics or ongoing integration issues from NuVasive and Nevro weigh on revenue growth and margins for longer than expected.

Next Steps

If this mix of optimism and caution has you thinking, do not wait for consensus to form. Instead, check the data that matters most to you and review the 5 key rewards

Looking for more investment ideas?

If you are serious about sharpening your portfolio, do not stop at a single stock. Use the Simply Wall Street Screener to spot fresh opportunities others might overlook.

• Target potential mispriced opportunities by scanning companies flagged as 50 high quality undervalued stocks that combine fundamentals with compressed expectations.
• Strengthen your income stream by reviewing stocks in the 12 dividend fortresses that offer higher yields with supporting fundamentals.
• Prioritize resilience by filtering for companies in the 66 resilient stocks with low risk scores that score well on risk and balance sheet strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.